Real-world effectiveness of adding newer generation GLP-1RA to SGLT2i in type 2 diabetes

Abstract Background Guidelines recommend combination therapy with glucagonlike peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) for cardiorenal risk reduction in people with type 2 diabetes (T2D); however, there is limited real-world evidence on the long...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Nathorn Chaiyakunapruk, Xi Tan, Yuanjie Liang, Mico Guevarra, Lin Xie, Alice Y. Y. Cheng
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2025-04-01
Edice:	Cardiovascular Diabetology
Témata:	Sodium-glucose cotransporter 2 inhibitor Glucagonlike peptide-1 receptor agonist Type 2 diabetes Atherosclerotic cardiovascular disease Chronic kidney disease Major adverse cardiovascular event
On-line přístup:	https://doi.org/10.1186/s12933-025-02737-1
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!